<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/85021">
      <dc:title>Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials</dc:title>
      <dc:creator>Huerta-Martínez, Miguel Ángel</dc:creator>
      <dc:creator>García Martínez, José Miguel Ángel</dc:creator>
      <dc:subject>Neuropathic pain</dc:subject>
      <dc:subject>Analgesics</dc:subject>
      <dc:subject>First in class</dc:subject>
      <dc:subject>AT2R</dc:subject>
      <dc:subject>AAK1</dc:subject>
      <dc:subject>LANCL</dc:subject>
      <dc:subject>Nerve growth factor</dc:subject>
      <dc:subject>COX</dc:subject>
      <dc:subject>Opioid</dc:subject>
      <dc:subject>NMDA</dc:subject>
      <dc:description>The pharmacological treatment of postherpetic neuralgia (PHN) is unsatisfactory, and&#xd;
there is a clinical need for new approaches. Several drugs under advanced clinical development are&#xd;
addressed in this review. A systematic literature search was conducted in three electronic databases&#xd;
(Medline, Web of Science, Scopus) and in the ClinicalTrials.gov register from 1 January 2016 to&#xd;
1 June 2023 to identify Phase II, III and IV clinical trials evaluating drugs for the treatment of PHN.&#xd;
A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on&#xd;
nine different molecular targets: Angiotensin Type 2 Receptor (AT2R) antagonism (olodanrigan),&#xd;
Voltage-Gated Calcium Channel (VGCC)  2  subunit inhibition (crisugabalin, mirogabalin and pregabalin),&#xd;
Voltage-Gated Sodium Channel (VGSC) blockade (funapide and lidocaine), Cyclooxygenase-1&#xd;
(COX-1) inhibition (TRK-700), Adaptor-Associated Kinase 1 (AAK1) inhibition (LX9211), Lanthionine&#xd;
Synthetase C-Like Protein (LANCL) activation (LAT8881), N-Methyl-D-Aspartate (NMDA) receptor&#xd;
antagonism (esketamine), mu opioid receptor agonism (tramadol, oxycodone and hydromorphone)&#xd;
and Nerve Growth Factor (NGF) inhibition (fulranumab). In brief, there are several drugs in advanced&#xd;
clinical development for treating PHN with some of them reporting promising results. AT2R&#xd;
antagonism, AAK1 inhibition, LANCL activation and NGF inhibition are considered first-in-class&#xd;
analgesics. Hopefully, these trials will result in a better clinical management of PHN</dc:description>
      <dc:date>2023-10-16T09:28:09Z</dc:date>
      <dc:date>2023-10-16T09:28:09Z</dc:date>
      <dc:date>2023-08-20</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Huerta, M.Á.; Garcia, M.M.; García-Parra, B.; Serrano-Afonso, A.; Paniagua, N. Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials. Int. J. Mol. Sci. 2023, 24, 12987. [https://doi.org/10.3390/ijms241612987]</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10481/85021</dc:identifier>
      <dc:identifier>10.3390/ijms241612987</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución 4.0 Internacional</dc:rights>
      <dc:publisher>MDPI</dc:publisher>
   </ow:Publication>
</rdf:RDF>